Stanford University School of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2018

  1. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

    Journal of Clinical Oncology, Vol. 36, Núm. 11, pp. 1073-1079

2017

  1. Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

    Annals of Surgical Oncology, Vol. 24, Núm. 2, pp. 398-406

2015

  1. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

2014

  1. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

    The Lancet Oncology, Vol. 15, Núm. 2, pp. 156-163

2005

  1. Capecitabine plus docetaxel combination therapy: Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma

    Cancer, Vol. 103, Núm. 12, pp. 2455-2465